DICE Therapeutics (DICE) Stock Forecast, Price Target & Predictions
DICE Stock Forecast
DICE Therapeutics stock forecast is as follows: an average price target of $60.00 (represents a 26.18% upside from DICE’s last price of $47.55) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
DICE Price Target
The average price target for DICE Therapeutics (DICE) is $60.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $60.00. This represents a potential 26.18% upside from DICE's last price of $47.55.
DICE Analyst Ratings
According to 2 Wall Street analysts, DICE Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DICE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DICE Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 11, 2022 | Emily Bodnar | H.C. Wainwright | $60.00 | $40.25 | 49.07% | 26.18% |
| Jul 18, 2022 | Emily Bodnar | H.C. Wainwright | $40.00 | $16.06 | 149.07% | -15.88% |
The latest DICE Therapeutics stock forecast, released on Oct 11, 2022 by Emily Bodnar from H.C. Wainwright, set a price target of $60.00, which represents a 49.07% increase from the stock price at the time of the forecast ($40.25), and a 26.18% increase from DICE last price ($47.55).
DICE Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $47.55 | $47.55 | $47.55 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of DICE Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DICE Therapeutics's last price of $47.55. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2022 | Evercore ISI | Outperform | Outperform | Hold |
| Jul 18, 2022 | H.C. Wainwright | Buy | Initialise |
DICE Therapeutics's last stock rating was published by Evercore ISI on Oct 11, 2022. The company gave DICE a "Outperform" rating, the same as its previous rate.
DICE Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.38 | $33.86 | 1322.69% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.78 | $7.00 | 293.26% | Buy |
| TERN | Terns Pharmaceuticals | $5.77 | $18.67 | 223.57% | Buy |
| PLRX | Pliant Therapeutics | $13.56 | $35.50 | 161.80% | Buy |
| IMCR | Immunocore | $29.18 | $70.20 | 140.58% | Buy |
| DYN | Dyne Therapeutics | $23.72 | $52.50 | 121.33% | Buy |
| AMLX | Amylyx Pharmaceuticals | $3.87 | $8.25 | 113.18% | Buy |
| CYTK | Cytokinetics | $47.36 | $90.00 | 90.03% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.87 | $24.00 | 86.48% | Buy |
| PCVX | Vaxcyte | $80.97 | $148.80 | 83.77% | Buy |
| MLTX | MoonLake Immunotherapeutics | $55.37 | $100.00 | 80.60% | Buy |
| EWTX | Edgewise Therapeutics | $28.74 | $46.25 | 60.93% | Buy |
| ASND | Ascendis Pharma | $137.50 | $211.14 | 53.56% | Buy |
| NUVL | Nuvalent | $80.30 | $114.80 | 42.96% | Buy |
| ACLX | Arcellx | $79.08 | $111.60 | 41.12% | Buy |
| CRNX | Crinetics Pharmaceuticals | $51.85 | $69.00 | 33.08% | Buy |
| VRDN | Viridian Therapeutics | $19.45 | $22.75 | 16.97% | Buy |